If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
239
results.
Updated on
15/07/2026 [07:04:00]
Results 75 to 100 of 239
Absstract of: WO2026147896A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having potency for treating disease. A nanomedicine platform is provided for various pharmacological uses. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Absstract of: WO2026147902A1
This invention relates to therapeutic deciparticle compositions and uses and methods thereof. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with auxiliary compounds such as a biologically active molecules. This invention further relates to methods for treating cancer with deciparticle compositions.
Absstract of: WO2026147899A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with a therapeutic agent. This invention further relates to methods for treating cancer, or providing immunosuppression for transplantation, or for treating severe rheumatoid arthritis with deciparticle compositions.
Absstract of: WO2026147900A1
This invention provides methods for making therapeutic deciparticle compositions and drug products thereof. Described herein are deciparticle compositions which can be composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticle (nanoparticle) compositions of this invention have potency for pharmacological effects for treating disease.
Absstract of: WO2026147897A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having anti-tumor potency. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Absstract of: WO2026147892A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having potency for anti-tumor effects. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Absstract of: WO2026147895A1
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having anti-cancer potency. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Absstract of: WO2026147683A1
Disclosed herein are biodegradable, ionizable lipids having a thioglycerol moiety, which are useful in forming lipid nanoparticles for delivery of therapeutic payloads, including nucleic acids. Pharmaceutical compositions and methods of using the same are also provided.
Absstract of: WO2026146128A1
The present invention relates to nanostructured lipid carriers (NLC) comprising vitamin D3 compounds, pharmaceutical compositions comprising the NLCs, and to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.
Absstract of: WO2026147080A1
The present invention provides an amine-based cyclolipid compound of chemical formula 1, and a pharmaceutically acceptable salt thereof. The amine-based cyclolipid compound according to the present invention is used as an ionizable lipid that is a component of lipid nanoparticles for delivering nucleic acids.
Absstract of: WO2026148182A1
The present invention relates to a coacervate composition of an alpha-helical antimicrobial peptide. In particular, the coacervate composition of the present invention exhibits reduced toxicity and increased dose tolerance compared to free alpha-helical antimicrobial peptide. The present invention also provides a method for preparing the coacervate composition, and a method for delivering an alpha-helical antimicrobial peptide and a method for treating bacterial infection using the coacervate composition. The present invention further provides a pharmaceutical composition preparing from the coacervate composition, and use of the coacervate composition for manufacturing a medicament for treating bacterial infection. In particular, the bacterial infection is caused by antibiotic resistant bacteria.
Absstract of: WO2026145659A1
An mRNA pharmaceutical composition for preventing and treating tuberculosis and a use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable adjuvant. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one Mycobacterium tuberculosis early secreted antigen or an immunologically active fragment thereof; at least one Mycobacterium tuberculosis PE/PPE family antigen or an immunologically active fragment thereof; and a Mycobacterium tuberculosis latency-associated antigen Rv2029c or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, can be used as a preventive vaccine for preventing latency reactivation, can also be used as a therapeutic drug for treating active tuberculosis, and has a significant inhibitory effect on Mycobacterium tuberculosis.
Absstract of: WO2026147352A1
The present disclosure concerns use of a nanocapsule for thermal regulation of hair, scalp, and/or skin, comprising a step of contacting the nanocapsule with the hair, scalp, and/or skin; wherein the nanocapsule comprises a shell and a core; wherein the core comprises a phase change material configured to absorb heat from the hair, scalp, skin and/or an environment adjacent to the hair, scalp, and/or skin. The present disclosure also concerns a method of cooling hair, scalp and/or skin.
Absstract of: WO2026148310A1
Disclosed are compounds and compositions that preferentially target cancer cells with a warhead that comprises a chemotherapeutic agent releasably bound to a targeting agent where the chemotherapeutic agent is released upon cellular absorption. Also disclosed are methods of use.
Absstract of: WO2026145679A1
A carrier-drug conjugate, and a preparation method therefor and a use thereof, relating to the technical fields of biomedical technology, nanomedicine, and drug delivery. The carrier-drug conjugate is a non-absorbable carrier-drug conjugate, comprising a non-absorbable carrier unit, a linker, and a receptor binding agent unit. The non-absorbable carrier-drug conjugate exhibits a variation in hydrodynamic diameter of no more than 5% within 24 hours in a gastrointestinal tract physiological environment, and the proportion absorbed within 24 hours in the gastrointestinal tract physiological environment does not exceed 1%. When the non-absorbable carrier-drug conjugate is administered via a gastrointestinal tract, the non-absorbable carrier-drug conjugate remains stable in a gastrointestinal tract environment and is not absorbed by the gastrointestinal tract into systemic circulation. Therefore, the non-absorbable carrier-drug conjugate can specifically bind to targets on the surface of gastrointestinal tract cells, overcoming the limitations of conventional drug administration where drugs act on targets throughout a body, and reducing side effects.
Absstract of: US20260193647A1
0000 A nanomedicine platform that involves the use of a blood brain-permeable tumor-navigating probe that includes a peptide p28 covalently linked with antisense miRNA. The probe localized in intracerebral human pediatric glioblastoma tumors in mice. Upon cellular entry, the probe significantly inhibits tumor cell viability by silencing the oncogenic miRNA miR-20a. Notably, systemic administration of the probe enabled complete regression of the ear-ly-stage tumor and significantly prolonged overall survival without apparent adverse effects.
Absstract of: WO2025048714A1
There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein A comprises a carbohydrate and/or a derivative thereof; R1 and R2 are each independently a hydrophobic group; R3, R4, R5, and R6 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7, R9 and R10 are each independently optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R8 is –O–, –S–, or –NRa–, where Ra is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; m is 0 or 1; n ≥ 1; and w ≥ 1.
Absstract of: WO2025049579A1
The invention provides intranasal formulation for pulmonary delivery of nanoparticles, compositions, uses, and manufacturing methods thereof. In one aspect, an intranasal formulation for intranasal or intrapulmonary administration includes a viscosity agent, an epithelial adherence agent, and a foaming agent. The viscosity agent may include carboxymethylcellulose, the epithelial adherence agent may include poly-lysine, and the foaming agent may include gelatin hydrolysate.
Absstract of: EP4772512A1
The present disclosure discloses drugs for preventing and/or treating Alzheimer's disease (AD). A CF3CN derivative provided by present disclosure has any one of structural formulas 1-4 shown below. All four CF3CN derivatives have TrkB agonist activities; and specifically, the CF3CN derivative shown in formula 2 serves as an optimal derivative. In vivo PK studies reveal that the CF3CN derivative shown in the formula 2 is capable of improving a B/P Ratio of CF3CN, and overcoming the limitations of CF3CN. Nanoparticles are prepared by encapsulating the CF3CN derivatives with zein and lactoferrin, which may further enhance an oral bioavailability and a brain drug concentration, thereby improving AD treatment effects. By further improving the formulation and administration route, a liposome is employed to encapsulate the CF3CN derivative for both oral and intranasal administration, which effectively solves the problems of low bioavailability and low brain drug concentration of the derivative.
Absstract of: WO2025049925A2
The present disclosure provides compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications.
Absstract of: WO2025003756A2
The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNAs) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w/w) than the mRNA encoding the influenza B virus, and methods of eliciting an immune response by administering said compositions. In particular, the disclosures relate to mRNA encoding these antigens formulated in a lipid nanoparticle (LNP).
Absstract of: WO2025046121A1
Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least an ionizable lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the ionizable lipid fraction comprises at least one ionizable glycerol dialkyl glycerol tetraether (GDGT) lipid. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine. In a further aspect, the invention relates to the ionizable GDGT lipids and methods for producing them.
Absstract of: WO2025045142A1
Disclosed herein are immunogenic compositions having circular RNAs encoding VEGF polypeptides. Related methods for manufacture and therapeutic uses thereof are also provided herein.
Absstract of: WO2025049816A1
A method for inserting a polynucleotide exogenous transgene sequence at a pre- determined endogenous genetic locus in a hose cell genome includes: (i) a donor DNA template including a polynucleotide insert; a 5 '-homology arm; and a 3 '-homology arm. In some embodiments, the 5' homology arm and the 3' homology arm are complementary to the DNA in a target region; and (ii) a ribonucleoprotein complex (RNP) including (1) a Cas nuclease, and at least one small guide RNAs (sgRNA) that is complementary to at least one selected nucleic acid sequence within the pre-determined genetic locus in the host cell genome.
Nº publicación: EP4770615A1 08/07/2026
Applicant:
UNIV TENNESSEE RES FOUND [US]
University of Tennessee Research Foundation
Absstract of: WO2025050106A1
The present disclosure relates to the field of ocular implants suitable for sustained release of drugs (e.g., water-soluble drugs) and use of the ocular implants for treatment of ocular conditions, including glaucoma.
BOPI
Electronic site
